Typewriter Therapeutics
Summary active Updated Sep 2, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Typewriter Therapeutics is a Cambridge, Massachusetts–based genetic medicines company developing RNA-based therapies built on scientific-founder Professor Emeritus Haruhiko Fujiwara’s (University of Tokyo) work on “jumping gene” R2 RNA elements, which insert therapeutic DNA into targeted safe-harbor genomic sites without viral vectors 123. The platform delivers gene-writing machinery via lipid nanoparticles and is initially aimed at cancer (in vivo CAR-T cell therapies) and severe genetic diseases, including genetic liver diseases 123. RA Capital originally seeded the company as a NewCo in 2023 3.
On September 2, 2026, Typewriter emerged from stealth with a $56 million Series A financing co-led by AN Venture Partners and RA Capital Management, with participation from ANRI, Gemseki, and SBI US Gateway Fund 12. The round was disclosed alongside the appointment of Matthew Stanton, PhD as Chief Executive Officer, Leanne Peiser, DPhil as Chief Scientific Officer, and Mikael Dolsten, MD, PhD (former Pfizer Chief Scientific Officer) as Board Director 1. The company maintains research operations in both Cambridge, Massachusetts and Tokyo, Japan 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-09-02 | Series A | $56M | AN Venture Partners, RA Capital Management | ANRI, Gemseki, SBI US Gateway Fund 12 |
What Investors Say
No independently sourced investor quotes found at time of profile creation.
What Founders Say
Matthew Stanton, PhD, CEO: “By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines.” 1
Sources
-
PR Newswire, “Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines,” September 2, 2026, accessed September 2026. https://www.prnewswire.com/news-releases/typewriter-therapeutics-emerges-from-stealth-with-56-million-series-a-financing-to-pursue-in-vivo-car-t-medicines-302866871.html↩↩↩↩↩↩↩
-
Endpoints News, “Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies,” September 2, 2026, accessed September 2026. https://endpoints.news/typewriter-raises-56m-for-jumping-gene-technology-and-in-vivo-car-t-therapies/↩↩↩↩
-
RA Capital, “Typewriter Therapeutics — Portfolio,” accessed September 2026. https://www.racap.com/portfolio/typewriter-therapeutics↩↩↩